Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastomaL Chen(Newcastle University), Deborah A. Tweddle(Newcastle University)British Journal of CancerJune 12, 201410.1038/bjc.2014.325Cited by 42SaveCiteExport RISWatch citationsRelated PapersPre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma|Oncotarget|2015|89